Pharma company with a Mcap of just Rs 157 crore bagged a whopping Rs 600 crore order; are you tracking this microcap stock?

Karan Dsij
/ Categories: Trending, Mindshare
Pharma company with a Mcap of just Rs 157 crore bagged a whopping Rs 600 crore order; are you tracking this microcap stock?

As investors continue to keep a close eye on this microcap stock, one thing is certain

The Nifty benchmark index experienced a volatile day of trading, closing marginally higher at 17398, up 0.22 percent. Despite a lacklustre performance from domestic equities ahead of the RBI policy meeting outcome, the auto sale numbers and three-month high manufacturing data provided a much-needed boost to the sectoral front. Auto and PSU Bank indices gained 1 percent each, while the realty index saw nearly one percent increase. However, selling was seen in the FMCG, metal, power, oil & gas and information technology stocks.  

While the broader market indices remained relatively stagnant, there is one stock that has caught the attention of investors and traders alike - Vaishali Pharma. This Mumbai-based company is engaged in the supply of pharmaceutical products to corporates, hospitals and retail stores in all SKUs required. With its innovative approach and consistent agility, Vaishali Pharma has established a strong foothold both domestically and internationally. Its products have made an impact in the overseas market and are receiving excellent feedback worldwide.  

The company's recent supply order worth Rs 600 crore from an overseas buyer for the purchase of Antibiotics Pharmaceutical products is a testament to its commitment to meeting the needs of its customers. The order is set to be executed within 6 to 8 months, which is a remarkable feat for a company of its size.  

As a result of these recent developments, Vaishali Pharma's stock has jumped over 2 percent to Rs 149.20 on Monday. In fact, the stock has been on a tear in the last year, delivering multibagger returns of over 130 percent. This is a clear indication of the company's dedication to excellence and its ability to remain resilient in an unpredictable market.  

In conclusion, while the market remains choppy and uncertain, Vaishali Pharma stands out as a shining example of success and innovation in the pharma industry. Its recent achievements and multibagger returns are a testament to the company's unwavering commitment to providing high-quality products and meeting the needs of its customers. As investors continue to keep a close eye on this microcap stock, one thing is certain - Vaishali Pharma is a company to watch out for in the coming years.  

Rate this article:
3.8

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary28-Mar, 2024

Expert Speak29-Mar, 2024

Mindshare29-Mar, 2024

Multibaggers28-Mar, 2024

Interviews28-Mar, 2024

Knowledge

General26-Mar, 2024

MF25-Mar, 2024

General18-Mar, 2024

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR